STAT

STAT Plus: Pharmalittle: BioNTech expects to seek approval for vaccine by year-end; why the FDA chose a 50% threshold for Covid-19 vaccines

Peter Marks, a top FDA official, shed light on the reasoning behind the agency's choice of a 50% efficacy threshold for a Covid-19 vaccine.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks